EAUTV daily show - oligometastatic prostate cancer

The conversation begins with Dr. Buteau presenting the key findings of the “PRIMARY 2” trial and discussing how advanced imaging such as PSMA PET is reshaping the detection and definition of oligometastatic disease, as well as its implications for treatment selection. Prof. Casuscelli then addresses the role of systemic therapy intensification and how clinicians can balance aggressive treatment with the risk of overtreatment, particularly in younger patients. Together, the panel reflects on new trial data comparing systemic therapy alone versus combined approaches including treatment of the primary tumour, and considers how future clinical trials should be designed to better guide therapeutic strategies in oligometastatic disease.